t
Genus plc announced on May 9, 2025, the appointment of J.P. Morgan Securities plc (J.P. Morgan Cazenove) as its Financial Adviser and joint Corporate Broker. This appointment is effective immediately, with J.P. Morgan Cazenove serving alongside existing corporate brokers Peel Hunt and Panmure Liberum.
| Date | 9 May 2025 |
| Time | 09:25:53 |
| Category | Miscellaneous |
| ID | 0757I |
09 May 2025
Genus plc ("Genus" or the "Group")
Appointment of new Financial Adviser and joint Corporate Broker
Genus (LSE: GNS), a leading global animal genetics company, announces the appointment of J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove) as its Financial Adviser and joint Corporate Broker, alongside Peel Hunt and Panmure Liberum, with immediate effect.
For further information please contact:
Genus plc Tel: +44 125 634 5970
Jorgen Kokke, Chief Executive Officer
Alison Henriksen, Chief Financial Officer
Anand Date, Investor Relations & Sustainability Director
Burson Buchanan Tel: +44 207 466 5000
Charles Ryland; Toto Berger; Sophie Wills; Verity Parker
About Genus
Genus is a world-leading animal genetics company. Genus creates advances in animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.
Genus's worldwide sales are made in over seventy-five countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus's customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chains.
The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network. The PRP is a market leading innovation in gene editing, which Genus is looking to commercialise in the porcine industry once regulatory approval is gained.
With headquarters in Basingstoke, United Kingdom, Genus companies operate in over twenty-five countries on six continents, with research laboratories located in Madison, Wisconsin, USA.